Patents by Inventor Martin Winn

Martin Winn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Endothelin antagonists
    Patent number: 6462194
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: October 8, 2002
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Treatment of diseases using endothelin antagonists
    Patent number: 6380241
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: April 30, 2002
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Remote tracing of data processing nodes in an asynchronous messaging network
    Publication number: 20020049801
    Abstract: Remote tracing from a local data processing node of the execution of a process within an application program running on a remote data processing node in a distributed data processing network. The application program includes its own local trace facility and the nodes communicate by asynchronous messaging via mailboxes. Each node includes process-private interrupt handling means for indicating the presence of a command for the respective process in the mailboxes.
    Type: Application
    Filed: March 26, 2001
    Publication date: April 25, 2002
    Applicant: International Business Machines Corporation
    Inventors: Stephen John Beynon, Brian Kenneth Mihell, Andrew Mark Swinson, Geoffrey Martin Winn
  • Glucocorticoid receptor antagonists for treatment of diabetes
    Patent number: 6329534
    Abstract: Compounds of formula I are useful for treating type II diabetes, obesity, hyperglycemia, inadequate glucose clearance, hyperinsulinemia, hypertriglyceridemia, and high-circulating glucocorticoid levels, preparations of the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: December 11, 2001
    Assignee: Abbott Laboratories
    Inventors: Philip R. Kym, Benjamin C. Lane, John K. Pratt, Tom Von Geldern, Martin Winn, Jehrod Brenneman, Jyoti R. Patel, David L. Arendsen, Irini Akritopoulou-Zanze
  • Glucocorticoid receptor antagonists for treatment of diabetes
    Publication number: 20010041802
    Abstract: 1
    Type: Application
    Filed: February 28, 2001
    Publication date: November 15, 2001
    Inventors: Philip R. Kym, Benjamin C. Lane, John K. Pratt, Tom Von Geldern, Martin Winn, Jehrod Brenneman, Jyoti R. Patel, David L. Arendsen, Irini Akritopoulou-Zanze, Kimba L. Ashworth, Kresna Hartandi
  • Endothelin antagonists
    Patent number: 6162927
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: December 19, 2000
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Endothelin antagonists
    Patent number: 6124341
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: September 26, 2000
    Assignee: Abbott Laboratories
    Inventors: Andrew S. Tasker, Martin Winn, Steven A. Boyd, Hwan-Soo Jae, Thomas W. von Geldern, Bryan K. Sorensen, Kenneth J. Henry
  • Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
    Patent number: 6110922
    Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: August 29, 2000
    Assignee: Abbott Laboratories
    Inventors: James Link, Gang Liu, Zhonghua Pei, Tom von Geldern, Martin Winn, Zhili Xin
  • Endothelin antagonists
    Patent number: 5767144
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 16, 1998
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen
  • Endothelin antagonists
    Patent number: 5731434
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 24, 1998
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen
  • Endothelin antagonists
    Patent number: 5622971
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 22, 1997
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen
  • Angiotensin II receptor antagonists
    Patent number: 5326776
    Abstract: Compounds are disclosed having the formula: ##STR1## wherein the substituents are defined herein. The compounds of the invention are angiotensin II receptor antagonists.
    Type: Grant
    Filed: February 24, 1993
    Date of Patent: July 5, 1994
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Biswanath De, Thomas M. Zydowsky, Daniel J. Kerkman, John F. DeBernardis, Saul H. Rosenberg, Kazumi Shiosaki, Fatima Z. Basha, Kenneth P. Spina, Thomas W. von Geldern, Steven Boyd, Diane M. Yamamoto, Anthony K. L. Fung
  • Angiotensin II receptor antagonists
    Patent number: 5250548
    Abstract: Compounds are disclosed having the formula: ##STR1## The compounds of the invention are angiotensin II receptor antagonists.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: October 5, 1993
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Biswanath De, Thomas M. Zydowsky, Daniel J. Kerkman, John F. DeBernardis, Saul H. Rosenberg, Kazumi Shiosaki, Fatima Z. Basha, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Steven Boyd, Diane M. Yamamoto, Anthony K. L. Fung
  • Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
    Patent number: 4665095
    Abstract: Disclosed herein are alpha adrenergic and nasal decongestant compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2, each being the same or different, are halogens, and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 11, 1985
    Date of Patent: May 12, 1987
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, John F. Debernardis
  • 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles useful in the treatment of hypertension
    Patent number: 4622405
    Abstract: Disclosed herein are 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles represented by the formula ##STR1## wherein R.sub.1 is hydrogen, loweralkyl of 1 to 5 carbon atoms, arylalkyl, loweracyl or benzoalkylenedioxy; R.sub.2 and R.sub.3 may be the same or different and are hydroxy, loweralkoxy, halo, thiomethyl, loweracyl, NR.sub.4 R.sub.5, NHSO.sub.2 R.sub.6 or arylalkoxy or R.sub.2 and R.sub.3 taken together may form a methylenedioxy or ethylenedioxy bridge; R.sub.4 and R.sub.5 may be the same or different and are hydrogen, loweralkyl of 1 to 2 carbon atoms or loweracyl; and R.sub.6 is hydrogen or loweralkyl of 1 to 2 carbon atoms.
    Type: Grant
    Filed: January 28, 1985
    Date of Patent: November 11, 1986
    Assignee: Abbott Laboratories
    Inventors: John F. DeBernardis, Martin Winn
  • Aminoalkyl dihydronaphthalenes
    Patent number: 4473586
    Abstract: Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.
    Type: Grant
    Filed: May 3, 1982
    Date of Patent: September 25, 1984
    Assignee: Abbott Laboratories
    Inventors: John F. Debernardis, David L. Arendsen, Martin Winn
  • 2-(4-Phenylalkanoylpiperazin-1-yl) quinazoline compounds, pharmaceutical compositions and method of producing .alpha..sub.1 antagonistic activity
    Patent number: 4440769
    Abstract: 4-amino-6,7-dimethoxy-2-(4-phenylalkanoylpiperazin-1-yl) quinazolines having .alpha..sub.1 -adrenergic receptor antagonistic activity. These compounds are useful in the treatment of hypertension.
    Type: Grant
    Filed: February 11, 1983
    Date of Patent: April 3, 1984
    Assignee: Abbott Laboratories
    Inventors: John F. DeBernardis, Martin Winn
  • Pyrazolyl amino imidazolines as antihypertensive agents
    Patent number: 4234594
    Abstract: Described is a method of treating hypertensive by administering to mammalian patients compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen, loweralkyl, lowercycloalkyl, aralkyl, aryl, pyridyl, isoquinolyl, phthalazinyl, or aryl substituted by one or more hydrogen, halo, loweralkyl, lowercycloalkyl, haloloweralkyl, haloloweralkyl, aminosulfonyl, nitro, hydroxy, alkoxy, carboxy, alkoxycarbonyl, cycloalkoxy carbonyl, aminocarbonyl, diloweralkylaminocarbonyl or ##STR2## wherein n is 4 or 5.R.sub.3 is hydrogen, halogen, loweralkyl or aryl, andR.sub.4 is hydrogen, acyl, amino or loweralkyl, and the pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: May 7, 1979
    Date of Patent: November 18, 1980
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Carl W. Nordeen, David L. Arendsen
  • 2-(N-phenethyl-4-piperidino)-5-pentyl resorcinol
    Patent number: 4180669
    Abstract: This invention provides 2-(N-substituted piperidino)-5-alkyl resorcinols of the structure ##STR1## wherein R.sub.1 is H, loweralkyl, loweralkynyl or aralkyl; R.sub.2 and R.sub.3 are each H or when taken together R.sub.2 R.sub.3 =CH.sub.2 CH.sub.2 ; R.sub.4 is a C.sub.1 -C.sub.10 alkyl and R.sub.5 is H or loweralkyl, and the pharmaceutically acceptable salts thereof.These compounds are useful as antisecretory agents.
    Type: Grant
    Filed: March 27, 1978
    Date of Patent: December 25, 1979
    Assignee: Abbott Laboratories
    Inventor: Martin Winn
  • Aminomethylene oxindoles
    Patent number: 4176191
    Abstract: This invention provides aminomethylene oxindole compounds represented by the formula ##STR1## wherein R is H or loweralkyl; R' is loweralkyl, aralkyl, or R and R' taken together form a chain of the formula--CH.sub.2 CH.sub.2 X CH.sub.2 CH.sub.2 --wherein X is CH.sub.2 or NR" where R" is loweralkyl, loweralkanoyl, aroyl, alkoxycarbonyl or aryl; and the pharmaceutically acceptable acid addition salts thereof.The compounds of this invention are useful as antihypertensive agents.
    Type: Grant
    Filed: November 6, 1978
    Date of Patent: November 27, 1979
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, John J. Kyncl